Search results
Low-dose glucocorticoids in systemic lupus erythematosus: New evidence around use and thresholds
Medical Xpress· 4 days agoGlucocorticoids are a mainstay of treatment for systemic lupus erythematosus (SLE). But due to...
Fate Therapeutics stock upgraded by Piper Sandler on autoimmune focus By Investing.com
Investing.com· 5 hours agoThe biopharmaceutical company, known for its work in developing programmed cell therapies for cancer...
What Is a T-Cell Lymphoproliferative Disorder? Inside Halsey's Diagnosis
Health.com· 5 days agoHalsey, 29, was diagnosed and treated for both lupus and a rare white blood cell disorder, according...
Citi maintains Buy rating on Cabaletta Bio post-EULAR data By Investing.com
Investing.com· 3 hours agoOn Monday, Citi reaffirmed its positive stance on Cabaletta Bio Inc . The endorsement follows the...
Identifying predictors for organ damage in children with systemic lupus erythematosus
Medical Xpress· 3 days agoAt their 2024 congress, EULAR—The European Alliance of Associations for Rheumatology—ran a session...
Doctors Recommend These Self-Care Practices For People Living With The Autoimmune Disease
Woman's World via Yahoo News· 6 days agoWhat is lupus? There are a few variations of lupus. According to the Lupus Research Alliance, the...
CAR-T Treatment Continues to Astonish in Rheumatologic Diseases
MedPage Today· 5 days agoNew data reported here reinforce the idea that chimeric antigen receptor T-cell (CAR-T) therapy can...
Mouth Ulcer
Health via Yahoo News· 2 days agoThe exact cause of mouth ulcers is unknown. An injury inside your mouth from braces or a virus can lead to a mouth ulcer. Health conditions like...
Late-breaking results show nipocalimab significantly improves Sjögren's disease activity in a Phase...
The Woonsocket Call· 2 days agoJohnson & Johnson (NYSE: JNJ) announces patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo ...
Cabaletta's 2-patient CAR-T data hint at autoimmune remission, but investors want more
FierceBiotech· 3 days agoThe data came from the first two patients who received Cabaletta’s CABA-201 in the phase 1/2...
